Sažetak
Uvod/Cilj. Hirurška resekcija jetre predstavlja metod izbora u lečenju pojedinačnih metastaza kolorektalnog karcinoma u jetri kod odgovarajućih bolesnika. Radiofrekventna ablacija postaje sve popularnija metoda za lečenje metastaza u jetri. Cilj ove studije bio je da uporedi ishode bolesti kod bolesnika sa pojedinačnom metastazom kolorektalnog karcinoma u jetri koji su lečeni hirurškom resekcijom u odnosu na bolesnike koji su lečeni radiofrekventnom ablacijom (RFA). Metode. U ovoj retrospektivnoj studiji analizirani su bolesnici sa pojedinačnom metastazom kolorektalnog karcinoma u jetri koji su lečeni u KBC „Dr Dragiša Mišović“ u Beogradu u periodu od januara 2002. do decembra 2009. godine. Poređeni su ishodi bolesti nakon hirurške resekcije jetre i nakon RFA metastaza u jetri. Rezultati. Studijom je bilo obuhvaćeno 94 (67,1%) bolesnika podvrgnutih resekciji jetre, dok je 46 (32,9%) bolesnika lečeno radiofrekventnom ablacijom. Kod većine bolesnika (59,6%) podvrgnutih hirurškoj resekciji učinjena je major hepatektomija. Prosečna dužina praćenja bolesnika bila je 28,4 meseca. Utvrđeno je da RFA tumora predstavlja značajni prediktor dužine ukupnog preživljavanja (p = 0,002, OR 3,75, 95% CI 1,696–8,284), te da je duže preživljavanje bez tegoba bilo u grupi bolesnika sa resekcijom u poređenju sa RFA grupom (37,6 vs 22,3 meseca, p = 0,073). Prosečno ukupno preživljavanje iznosilo je 56,3 meseca u grupi bolesnika sa hirurškom resekcijom naspram 25,1 mesec u RFA grupi (p = 0,005). Zaključak. Kod odgovarajućih bolesnika sa pojedinačnom metastazom kolorektalnog karcinoma u jetri trebalo bi razmotriti hiruršku resekciju kad god je to izvodljivo, jer pruža duži period preživljavanja nego lečenje radiofrekventnom ablacijom.
Ključne reči
||kolorektalne neoplazme
digestive system surgical procedures||
||hirurgija digestivnog sistema
procedure
liver neoplasms||
||jetra
neoplazme
neoplasm metastasis||
||neoplazme
metastaze
catheter ablation
treatment outcome||
||ablacija preko katetera lečenje
ishod
Reference
Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after ra-diofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246(4): 559−65; discussion 565−7.
Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006; 32(3): 214−28.
Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239(6): 818−25; discussion 825−7.
Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90(10): 1240−3.
Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141(5): 460−6; discussion 466−7.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for me-tastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230(3): 309−18; discussion 318−21.
Cummings LC, Payes JD, Cooper GS. Survival after hepatic resec-tion in metastatic colorectal cancer: a population-based study. Cancer 2007; 109(4): 718−26.
Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the frontiers of surgical indica-tions in the treatment of liver metastases from colorectal can-cer: long-term results. Ann Surg 2000; 231(4): 487−99.
Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: mini-mum surgical margins for successful resection. Arch Surg 2002; 137(7): 833−40.
Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg 1998; 22(3): 268−76; discussion 276−7.
Siperstein A, Garland A, Engle K, Rogers S, Berber E, Foroutani A, et al. Local recurrence after laparoscopic radiofrequency ther-mal ablation of hepatic tumors. Ann Surg Oncol 2000; 7(2): 106−13.
McKay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg 2009; 2009: 346863..
Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Com-parative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009; 197(6): 728−36.
McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006; 93(10): 1192−201.
Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7(8): 593−600.
Feliberti EC, Wagman LD. Radiofrequency ablation of liver me-tastases from colorectal carcinoma. Cancer Control 2006; 13(1): 48−51.
Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am 2002; 82(5): 1075−90, x−xi.
Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofre-quency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol 2008; 15(1): 144−57.